SMARCB1 and neoplasm: Immunohistochemistry (IHC) revealed tumor cells negative for AE1/AE3, PAX8, OCT4, CD34, SALL4, chromogranin, synaptophysin, NGFR CD20, WT1, cyclin D1, and SATB2, with lost expression of BRM (SMARCA2) and retained expression of INI1 (SMARCB1) and BRG (SMARCA4).